Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dendritic cell vaccine (frameshift-derived neopeptides)
- Development stage
- Phase 1
- Lead developer
- IDIBAPS – the Hospital Clinic of the University of Barcelona
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
This dendritic cell vaccine is an autologous cell therapy developed by the Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer (IDIBAPS) for the prevention and treatment of cancers associated with Lynch syndrome. The vaccine is composed of a patient's own dendritic cells that have been matured and pulsed with a pool of shared frameshift-derived neopeptides (FSPs). These FSPs are highly immunogenic antigens that result from frameshift mutations in microsatellite unstable (MSI-H) cells, a hallmark of Lynch syndrome. By presenting these neoantigens to the immune system, the vaccine aims to prime and activate CD4+ and CD8+ T-lymphocytes to recognize and eliminate cells expressing these specific neopeptides, thereby providing a targeted immunotherapy against Lynch syndrome-related malignancies such as colorectal and endometrial cancers.
- Other names
- FSP-loaded DC vaccineLynch syndrome dendritic cell vaccineDendritic cell vaccine loaded with frameshift-derived neopeptides
02
Targets
Neoantigen-specific T-cell receptorpMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on dendritic cell vaccine (frameshift-derived neopeptides).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dendritic cell vaccine (frameshift-derived neopeptides).